ABSTRACT Introduction: There is little information on how to prioritize testis cancer (TC) patients' care during COVID-19 pandemic in order to relieve its pressure on the health care systems. Objective: To describe the recommendations for diagnosis, treatment and follow-up of patients with TC amidst COVID- 19 pandemic. Material and Methods: Pubmed search and review of the main urological association guidelines on TC. Results: The biology of TC requires immediate care of patients during diagnosis, initial surgical therapy and management of recurrent disease. Active surveillance is the first choice of management and should be offered to all compliant clinical stage I TC patients provided they understand the need to self-isolate. Active surveillance may also help decrease the demand for intensive care unit beds, ventilators, personal protective equipment, and other critical hospital and human resources by minimizing surgeries without compromising patient outcomes. Complications of therapy and symptomatic patients represent medical emergencies and should be treated immediately. Telemedicine may be useful during follow-up periods. Conclusions: Most stages of testis cancer require urgent care; however, all recommendations must be adapted to local health care priorities considering that most of these patients are at low risk of severe COVID-19 infection.

Advances in the understanding of prostate and pelvic anatomy in recent years made a substantial contribution to improve the surgical technique for the treatment of prostate cancer (PC) with the potential preservation of anatomic structures responsible for erectile and urinary function postoperatively. Knowledge of these anatomic structures is key to achieve a complete removal of the prostate and seminal vesicles while preserving the best possible quality of life. The literature on prostate and pelvic anatomy has been reviewed and an updated notion of the surgical anatomy is herein provided.

Los avances en la comprensión de la anatomía de la próstata y de la pelvis en los años recientes han significado una contribución sustancial para mejorar la técnica quirúrgica en el tratamiento del cáncer de próstata (CaP), con la preservación potencial de las estructuras anatómicas responsables de las funciones eréctil y urinaria postoperatoria. El conocimiento de estas estructuras anatómicas es la llave para conseguir una extirpación completa de la próstata y las vesículas seminales preservando a la vez la mejor calidad de vida posible. Revisamos la literatura sobre la anatomía de la próstata y la pelvis y hacemos una puesta al día de la anatomía quirúrgica.

OBJECTIVES: There is not enough evidence about efficacy in the treatment of stress urinary incontinence (SUI) after radical prostatectomy (RP). The objective of this paper is to describe our experience with the injection of pyrolytic carbon microspheres (Durasphere ®) in the treatment of SUI after RP. METHODS: Between January and October 2003 8 patients with the diagnosis of SUI after RP underwent treatment. Analyzed variables included age, time from RP to treatment, number of incontinence pads per day, operative report, subjective and objective response to treatment, and clinical-surgical outcomes. RESULTS: Mean age was 63.2 years (50-71). Median time from radical prostatectomy to injection was 25 months (14-134). No patient suffered urinary incontinence before radical prostatectomy. Median number of incontinence pads required before treatment with Durasphere ® injection was 2 per day (1-6). Mean Durasphere ® volume injected was 23.8 ml (15-30 ml). No patient achieved subjective or objective cure after treatment. After a median follow-up of 5 months (9.9-12.5) 5 patients (62.5%) chose to undergo a second more invasive treatment to solve their incontinence. CONCLUSIONS: The use of Durasphere ® as a permanent injectable agent did not result effective in the treatment of mild to moderate SUI after RP in our patients.

OBJETIVO: No existen datos suficientes en relación a la eficacia del tratamiento de la incontinencia urinaria de esfuerzo (IUE) después de prostatectomía radical (PR). El propósito de este estudio es describir nuestra experiencia mediante inyección de micro esferas de carbón pirolítico (Durasphere®) en el tratamiento de IUE tras PR. MÉTODOS: Entre Enero y Octubre de 2003 fueron tratados con Durasphere 8 pacientes con el diagnóstico de IUE después de PR. Se analizaron las variables edad, tiempo transcurrido desde la PR hasta el tratamiento, número diario de compresas, informe quirúrgico, respuesta subjetiva y objetiva al tratamiento, y evolución clínico quirúrgica. RESULTADOS: La edad media de los pacientes fue de 63,2 años (50-71). El tiempo mediano desde la prostatectomía radical hasta la inyección fue de 25 meses (14-134). Ningún paciente sufría incontinencia urinaria anterior a la prostatectomía radical. El número mediano de compresas usadas antes del tratamiento con Durasphere® era de 2 diarias (1-6). El volumen mediano de Durasphere® inyectado fue de 23.8 ml (15-30 ml). Ningún paciente resultó curado subjetiva u objetivamente después del tratamiento. Tras un seguimiento mediano de 5 meses (9.9-12.5), 5 pacientes (62.5%) optaron por un segundo tratamiento mas invasivo para resolver su incontinencia. CONCLUSIONES: La utilización de Durasphere® como agente inyectable permanente no supuso, entre nuestros pacientes un tratamiento efectivo de la IUE leve a moderada tras PR.